• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

71.09 -0.99 (-1.37%)
Delayed Quote Updated: 9:45 AM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,780
Open 71.48
Bid (Size) 70.85 (400)
Ask (Size) 71.33 (100)
Prev. Close 72.08
Today's Range 70.52 - 71.70
52wk Range 53.89 - 91.53
Shares Outstanding 42,600,000
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
October 14, 2026
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
September 29, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire

Performance

52-Week Range 22.3% below 52-week high
71.09
53.8952W Low 91.5352W High
1 Week 2.8% below 1-week high
67.931W Low 73.111W High

Tarsus Pharmaceuticals, Inc. - Common Stock (TARS) traded between $53.89 and $91.53 over the past 52 weeks and last traded at $71.09, 22.3% below its 52-week high. Over the past week it ranged between $67.93 and $73.11.

Past 12 Months
+4.4%
-7.8%
+21.4%
+16.6%
-12.0%
+3.5%
1W +$3.02
1M -$5.99
3M +$12.51
6M +$10.12
YTD -$9.68
1Y +$2.39

TARS was +3.5% over the past year, +16.6% over six months, -12.0% year to date, +4.4% in the last week.

12 Months vs Market
TARS
+3.5%
DIA
+12.1%
SPY
+13.9%
QQQ
+16.3%
IWM
+12.8%

Over the past 12 months TARS returned +3.5% versus DIA (Dow) +12.1%, SPY (S&P 500) +13.9%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +12.8%.

Volume & Liquidity 0.01× 3-mo avg
Today 9,780 3-mo avg 846.9K
1W
1.2M
1M
1.0M
3M
846.9K
6M
916.3K
YTD
783.4K
1Y
736.8K

TARS most recently traded 9,780 shares against a 3-month average daily volume of 846.9K.

More News

Read More
News headline image
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
September 04, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
September 01, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗
May 06, 2026
Via Chartmill
News headline image
Tarsus (TARS) Q2 2026 Earnings Call Transcript ↗
August 13, 2026
Via The Motley Fool
Topics Earnings
News headline image
Tarsus Pharmaceuticals Q2 Earnings Call Highlights ↗
August 07, 2026
Via MarketBeat
Topics Earnings
News headline image
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
August 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
August 05, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
July 13, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗
July 11, 2026
Via MarketBeat
News headline image
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
July 08, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗
July 01, 2026
Via Benzinga
Topics Law Enforcement
News headline image
Tarsus to Participate in Upcoming Investor Conferences
May 28, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
May 24, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
May 14, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
May 07, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q1 2026 Earnings Transcript ↗
May 06, 2026
Via The Motley Fool
News headline image
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
May 06, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
April 29, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
March 31, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗
March 24, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 71.09
When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 10/23/26 09:45 AM ET
What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 3.03B
How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap